首页> 美国卫生研究院文献>Cancer Science >RNA‐binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression
【2h】

RNA‐binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression

机译:RNA结合蛋白Musashi2稳定雄激素受体驱动前列腺癌进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The androgen receptor (AR) pathway is critical for prostate cancer carcinogenesis and development; however, after 18‐24 months of AR blocking therapy, patients invariably progress to castration‐resistant prostate cancer (CRPC), which remains an urgent problem to be solved. Therefore, finding key molecules that interact with AR as novel strategies to treat prostate cancer and even CRPC is desperately needed. In the current study, we focused on the regulation of RNA‐binding proteins (RBPs) associated with AR and determined that the mRNA and protein levels of AR were highly correlated with Musashi2 (MSI2) levels. MSI2 was upregulated in prostate cancer specimens and significantly correlated with advanced tumor grades. Downregulation of MSI2 in both androgen sensitive and insensitive prostate cancer cells inhibited tumor formation in vivo and decreased cell growth in vitro, which could be reversed by AR overexpression. Mechanistically, MSI2 directly bound to the 3′‐untranslated region (UTR) of AR mRNA to increase its stability and, thus, enhanced its transcriptional activity. Our findings illustrate a previously unknown regulatory mechanism in prostate cancer cell proliferation regulated by the MSI2‐AR axis and provide novel evidence towards a strategy against prostate cancer.
机译:雄激素受体(AR)通路对于前列腺癌的癌变和发展至关重要。然而,在18-24个月的AR阻滞治疗后,患者总是进展为去势抵抗性前列腺癌(CRPC),这仍然是一个亟待解决的问题。因此,迫切需要寻找与AR相互作用的关键分子作为治疗前列腺癌甚至CRPC的新策略。在当前的研究中,我们专注于与AR相关的RNA结合蛋白(RBPs)的调节,并确定AR的mRNA和蛋白水平与Musashi2(MSI2)水平高度相关。 MSI2在前列腺癌标本中上调,并与晚期肿瘤等级显着相关。雄激素敏感性和非敏感性前列腺癌细胞中MSI2的下调抑制了体内肿瘤的形成,并降低了体外细胞的生长,这可能被AR过表达逆转。从机制上讲,MSI2直接与AR mRNA的3'-非翻译区(UTR)结合,以增加其稳定性,从而增强其转录活性。我们的发现说明了由MSI2-AR轴调控的前列腺癌细胞增殖的未知机制,并为抗前列腺癌的策略提供了新的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号